In Vitro and In Vivo Characterization of an <sup>18</sup>F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing Xenografts.

Lütje, Susanne; Franssen, Gerben M; Herrmann, Ken; Boerman, Otto C; Rijpkema, Mark; Gotthardt, Martin; Heskamp, Sandra · J Nucl Med · 2019

basic_science · Level V

Where this comes from

Abstract

The aim was to compare the prostate-specific membrane antigen (PSMA)-targeting characteristics of PSMA-11, radiolabeled on the basis of chelation of <sup>18</sup>F-AlF, with those of <sup>68</sup>Ga-PSMA-11 to image PSMA-expressing xenografts. <b>Methods:</b> Labeling of <sup>18</sup>F-AlF-PSMA-11 via <sup>18</sup>F-AlF-complexation was performed as described by Boschi et al. and Malik et al. with minor modifications. Several conditions for the quality control of the labeling of <sup>18</sup>F-AlF-PSMA-11 via <sup>18</sup>F-AlF-complexation were evaluated to characterize the influence of ethanol, acetonitrile, and trifluoroacetic acid on the stability of the labeled product. Internalization kinetics of <sup>18</sup>F-AlF-PSMA-11 were compared with those of <sup>68</sup>Ga-PSMA-11 using PSMA-expressing LNCaP tumor cells. Biodistribution of <sup>18</sup>F-AlF-PSMA-11 (0.26 nmol/mouse, 8-9 MBq/mouse) in male BALB/c nude mice with PSMA-expressing subcutaneous LS174T-PSMA tumors was compared with that of <sup>68</sup>Ga-PSMA-11 at 1 and 2 h after injection. In addition, <sup>18</sup>F-AlF-PSMA-11 PET/CT and <sup>68</sup>Ga-PSMA-11 PET/CT imaging were performed at 1 and 2 h after injection. <b>Results:</b> In contrast to <sup>68</sup>Ga-PSMA-11, <sup>18</sup>F-AlF-PSMA-11 was not stable in water (radiochemical purity was 64.5% immediately after purification and 52.7% at 120 min after purification). <sup>18</sup>F-AlF-PSMA-11 remained relatively stable in 25 mM NH<sub>4</sub>OAc, pH 6.9, and radiochemical purity decreased from 98.5% at purification to 96.3%, 94.7%, and 92.5% at 60, 120, and 180 min after purification. In vitro, the <sup>18</sup>F- and <sup>68</sup>Ga-labeled compounds showed rapid internalization in LS174T-PSMA cells. The highest tumor uptake (percentage injected dose [%ID]) was observed at 2 h after injection (10.8 ± 2.3 %ID/g and 7.9 ± 1.3 %ID/g for <sup>18</sup>F-AlF-PSMA-11 and <sup>68</sup>Ga-PSMA-11, respectively [<i>P</i> > 0.05]). Renal tracer uptake peaked at 2 h after injection (43.5 ± 5.7 %ID/g and 105.8 ± 13.8 %ID/g for <sup>18</sup>F-AlF-PSMA-11 and <sup>68</sup>Ga-PSMA-11, respectively, <i>P</i> < 0.05). Bone uptake of <sup>18</sup>F-AlF-PSMA-11 was 3.3 ± 0.6 at 1 h after injection and 5.0 ± 0.6 %ID/g at 2 h after injection and was dependent on the radiochemical purity at the time of injection. Bone uptake of <sup>68</sup>Ga-PSMA-11 reached 0.1 ± 0.0 %ID/g at 1 and 2 h after injection. PSMA-expressing xenografts could be visualized using both <sup>68</sup>Ga-PSMA-11- and <sup>18</sup>F-AlF-PSMA-11 PET/CT. <b>Conclusion:</b> <sup>18</sup>F-AlF-PSMA-11 using direct labeling with aluminum fluoride can be produced in NH<sub>4</sub>OAc, pH 6.9; shows a high internalization rate; and visualizes PSMA-expressing tumors with similar tumor uptake. Lower kidney uptake than with <sup>68</sup>Ga-PSMA-11 may be advantageous for tumor detection. However, the limited instability and consequent Al<sup>18</sup>F uptake in bone might hamper the visualization of small PCa bone metastases.

Medical subject headings